title: Monthly administration of the LH-RH analogue decapeptyl for long-term treatment of ovarian dysfunctions and estrogen-dependent disorders.
abstract: The ovarian function of 11 patients suffering from estrogen-dependent disorders and ovarian dysfunction was suppressed by monthly administrations of an analogue of luteinizing hormone-releasing hormone (LH-RH). During the initial 11 to 18 days of treatment, the LH-RH analogue Decapeptyl was subcutaneously injected daily, followed by intramuscular administration of the peptide encapsulated in biodegradable microspheres at 30-day intervals over a 13- to 35-week period. After an initial increase on day 1 of treatment, serum levels of both LH and FSH declined, but did not reach hypogonadotropic values. The pituitary response in the release of both LH and FSH by a LH-RH bolus injection was almost completely suppressed during the treatment course. 17 beta-Estradiol serum levels decreased into the castration range within 9.1 +/- 4 days and remained low in 92% of the values estimated. In one patient, pretreatment mean testosterone levels on the order of 1.9 ng/mL were suppressed to normal within 14 days and remained low under therapy. Seven out of the 11 patients benefited from this therapy. In conclusion, the treatment with Decapeptyl in a slow-release formulation is an effective and suitable approach for the long-term suppression of ovarian function in estrogen-dependent disorders and ovarian dysfunctions.
authors.affiliation: Department of Obstetrics and Gynecology, University of Freiburg, F.R.G.
authors.forename: F
authors.initials: F
authors.lastname: Geisthoevel
authors.forename: K
authors.initials: K
authors.lastname: Hils
authors.forename: P
authors.initials: P
authors.lastname: Wieacker
authors.forename: M
authors.initials: M
authors.lastname: Breckwoldt
authors.forename: H
authors.initials: H
authors.lastname: Schultheiss
mesh_terms: D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy; D002214:Capsules; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004715:Endometriosis / Q000188:drug therapy; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy; D007279:Injections, Subcutaneous; D007889:Leiomyoma / Q000188:drug therapy; D007986:Luteinizing Hormone / Q000097:blood; D008186:Luteolytic Agents / Q000008:administration & dosage*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009839:Oligomenorrhea / Q000188:drug therapy; D010048:Ovarian Cysts / Q000188:drug therapy; D017329:Triptorelin Pamoate
chemical_list: D002214:Capsules; D003692:Delayed-Action Preparations; D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone